HIV has long stumped immunologists looking to develop an effective vaccine. All of the most promising approaches pioneered in the past three and a half decades have ultimately failed, and only a few months ago, the last trial expected to potentially deliver a vaccine within this decade was shut down.
But HIV scientists are nothing if not resilient, and used to trying one new approach after another. One of the latest and most promising centers around teaching the immune system to produce powerful and protective antibody responses through exposure to a series of different vaccine molecules. Researchers are already beginning to test this strategy in people, and on Thursday the strategy gained additional support from a set of four studies published in Science, Science Translational Medicine, and Science Immunology.
Click this link for the original source of this article.
Author: Annalisa Merelli and Jonathan Wosen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.